Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: The European FP7 UROMOL project

Journal of Urology

Volumn 189, Issue 5, 2013, Pages 1945-1951

  Zuiverloon, Tahlita C M ^a   Beukers, Willemien ^a   Van Der Keur, Kirstin A ^a   Nieuweboer, Annemieke J M ^a   Reinert, Thomas ^b   Dyrskjot, Lars ^b   Orntoft, Torben F ^b   Zwarthoff, Ellen C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

biological markers; neoplasm recurrence; receptor, fibroblast growth factor, type 3; urinary bladder; urinary bladder neoplasms

Indexed keywords

BIOLOGICAL MARKER; DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MICROSATELLITE DNA; PHOSPHATIDYLINOSITOL KINASE; PHOSPHATIDYLINOSITOL KINASE 3CA; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; CYSTECTOMY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DNA EXTRACTION; DNA METHYLATION; EUROPE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICTURITION; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION; URINALYSIS;

BIOLOGICAL MARKERS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 84876287017     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.11.115     Document Type: Article

References (29)

1. M. Babjuk, W. Oosterlinck, R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2008 303
2. D. Jocham, F. Witjes, S. Wagner Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study J Urol 174 2005 862
3. J.A. Witjes, J. Douglass The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer Nat Clin Pract Urol 4 2007 542
4. M.F. Botteman, C.L. Pashos, A. Redaelli The health economics of bladder cancer: a comprehensive review of the published literature Pharmacoeconomics 21 2003 1315
5. H. Hedelin, S. Holmang, L. Wiman The cost of bladder tumour treatment and follow-up Scand J Urol Nephrol 36 2002 344
6. J. Hosseini, A.R. Golshan, M.M. Mazloomfard Detection of recurrent bladder cancer: NMP22 test or urine cytology? Urol J 9 2012 367
7. E.C. Zwarthoff Detection of tumours of the urinary tract in voided urine Scand J Urol Nephrol 42 suppl. 2008 147
8. E. Dulaimi, R.G. Uzzo, R.E. Greenberg Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel Clin Cancer Res 10 2004 1887
9. M.G. Friedrich, D.J. Weisenberger, J.C. Cheng Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients Clin Cancer Res 10 2004 7457
10. M.O. Hoque, S. Begum, O. Topaloglu Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection J Natl Cancer Inst 98 2006 996
11. I. Renard, S. Joniau, B. van Cleynenbreugel Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples Eur Urol 58 2010 96
12. D.R. Yates, I. Rehman, M. Meuth Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls Oncogene 25 2006 1984
13. T. Reinert, C. Modin, F.M. Castano Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers Clin Cancer Res 17 2011 5582
14. T.C. Zuiverloon, W. Beukers, K.A. van der Keur A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine BJU Int 109 2012 941
15. M.N. van der Aa, E.C. Zwarthoff, E.W. Steyerberg Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]) Eur Urol 55 2009 659
16. B.W. van Rhijn, I. Lurkin, D.K. Chopin Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine Clin Cancer Res 9 2003 257
17. B.W. van Rhijn, M. Smit, D. van Geenen Surveillance with microsatellite analysis of urine in bladder cancer patients treated by radiotherapy Eur Urol 43 2003 369
18. M. Burger, M.N. van der Aa, J.M. van Oers Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study Eur Urol 54 2008 835
19. S. Hernandez, E. Lopez-Knowles, J. Lloreta Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas J Clin Oncol 24 2006 3664
20. A.H. Jebar, C.D. Hurst, D.C. Tomlinson FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma Oncogene 24 2005 5218
21. E. Lopez-Knowles, S. Hernandez, N. Malats PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors Cancer Res 66 2006 7401
22. T.C. Zuiverloon, M.N. van der Aa, T.H. van der Kwast Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer Clin Cancer Res 16 2010 3011
23. L.C. Kompier, I. Lurkin, M.N. van der Aa FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy PLoS One 5 2010 e13821
24. F.K. Mostofi, L.H. Sobin, I. Tosoni Histological typing of urinary bladder tumours International Histological Classification of Tumours, No. 10 1973 World Health Organization Geneva 485 566
25. J.M. van Oers, I. Lurkin, A.J. van Exsel A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine Clin Cancer Res 11 2005 7743
26. A.O. Nygren, N. Ameziane, H.M. Duarte Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences Nucleic Acids Res 33 2005 e128
27. T.C. Zuiverloon, S.S. Tjin, M. Busstra Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay J Urol 186 2011 707
28. B.W. van Rhijn, H.G. van der Poel, T.H. van der Kwast Urine markers for bladder cancer surveillance: a systematic review Eur Urol 47 2005 736
29. W. Otto, S. Denzinger, S. Bertz No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer Int J Cancer 125 2009 2205